Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Guilhem Roubaud, Marie Kostine, Raymond S. McDermott, Alice Bernard-Tessier, Xavier Maldonado, Marlon Silva, Aude Flechon, Dominik R. Berthold, Philippe Ronchin, Bertrand F. Tombal, Loic Mourey, Gwenaelle Gravis, Anne Escande, Sophie Abadie Lacourtoisie, Antoine Thiery-Vuillemin, Miguel Angel A. Climent Duran, Hélène Ribault, Alberto Bossi, Stéphanie Foulon, Karim Fizazi
Institutions: Institut Bergonié, Hôpital Pellegrin, St. Vincent's University Hospital, Institut Gustave Roussy, Vall d'Hebron Hospital Universitari, Centre Léon Bérard, Centre Hospitalier Universitaire Vaudois, Centre Azuréen de Cancérologie, UCLouvain, Institut Claudius Regaud, Aix-Marseille Université, Institut Paoli-Calmettes, Institut de Cancérologie de l'Ouest, Centre Hospitalier Universitaire de Besançon, Fundación Instituto Valenciano de Oncología, UniCancer Group, Université Paris-Saclay
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4213096313